This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
DENTSPLY to Acquire OraMetrix, Boost CAD-CAM Dental Unit
by Zacks Equity Research
The acquisition of OraMetrix is likely to bolster DENTSPLY's (XRAY) dental business.
Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks
by Gargi Seth
The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.
Here's Why You Should Steer Clear of DENTSPLY (XRAY) for Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) faces foreign exchange woes and chances of margin decline in the quarters ahead.
New Strong Sell Stocks for March 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.
Patterson Companies (PDCO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Diverse product portfolio and strong veterinary business prospects to drive Patterson Companies (PDCO) in Q3. However, sluggishness in the Dental-Supply segment is a woe.
Can Geographical Sales Aid DENTSPLY's (XRAY) Q4 Earnings?
by Zacks Equity Research
DENTSPLY (XRAY) anticipates lower regional sales to dent results in Q4. The company continues to focus on operational excellence.
Patterson Companies' (PDCO) Dental Segment Shows Weakness
by Zacks Equity Research
Changing healthcare environment in the United States, unfavorable price movements and competitive dental products industry are posing challenges for Patterson Companies, Inc. (PDCO).
Align Teams Up with Exocad to Expand in Digital Scanning
by Zacks Equity Research
Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.
Align Technology-Glidewell Dental Deal to Boost iTero Uptake
by Zacks Equity Research
Align Technology (ALGN) progresses with deals to boost the Scanners and Services segment.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.
DENTSPLY (XRAY) Q3 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
DENTSPLY reported adjusted earnings of 70 cents per share, which came above the Zacks Consensus Estimate by 4 cents and was higher than earnings of 66 cents in the year-ago quarter.
Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?
by Zacks Equity Research
In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
by Zacks Equity Research
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.
New Strong Sell Stocks for September 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.
DENTSPLY (XRAY) Q2 Earnings Miss Estimates, Sales Fall Y/Y
by Zacks Equity Research
DENTSPLY reported adjusted earnings of 65 cents per share, which missed the Zacks Consensus Estimate by a penny and was lower than earnings of 76 cents in the year-ago quarter.
4 Medical Product Stocks Likely to Top Q2 Earnings Estimates
by Zacks Equity Research
There are some powerful long-term tailwinds in the medical space.
Why DENTSPLY (XRAY) Might Surprise This Earnings Season
by Zacks Equity Research
DENTSPLY (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
DENTSPLY Sirona's (XRAY) results are likely to be boosted by surging dental & healthcare consumables space in the yet-to-be-reported second quarter.
Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?
by Zacks Equity Research
We expect second-quarter results of Flowserve (FLS) to gain traction from its strong operation model, solid productivity and geographical diversity.
Why an Earnings Beat is Likely for Waters Corp. (WAT) in Q2
by Zacks Equity Research
Waters Corp.'s (WAT) dominant position in the biopharma end markets and thriving sales in emerging markets will likely help it gain traction in the second quarter.